Tango Therapeutics, Inc. (TNGX) News
Filter TNGX News Items
TNGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TNGX News Highlights
- For TNGX, its 30 day story count is now at 3.
- Over the past 5 days, the trend for TNGX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- NOV are the most mentioned tickers in articles about TNGX.
Latest TNGX News From Around the Web
Below are the latest news stories about TANGO THERAPEUTICS INC that investors may wish to consider to help them evaluate TNGX as an investment opportunity.
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting– Data support the ongoing clinical development of TNG908 and TNG462 PRMT5 inhibitors for the treatment of MTAP-deleted cancers – BOSTON, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that two abstracts have been selected for poster presentations at the Society for Neuro-Oncology (SNO) 28th Annual Meeting taking plac |
Tango Therapeutics Inc (TNGX) Reports Q3 2023 Financial Results and Business UpdatesAdvancing Precision Oncology: Tango Therapeutics Highlights Clinical Progress and Financial Health |
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nexte |
Tango Therapeutics to Present at the Jefferies London Healthcare ConferenceBOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023 at 1:00 PM GMT. A live webcast of the presentation will be available under the "Even |
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been selected for poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023 in Boston, Massachusetts. Abstracts accepted for poster presentation Title: |
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersBOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for TNG348, a novel inhibitor of USP1 (ubiquitin-specific protease 1), for the treatment of BRCA1/2 mutant and other HRD+ (homologous recombination defi |
Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceBOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 4:00 PM ET. A live webcast of the presentation will be ava |
Tango Therapeutics Announces Updates to Its Board of DirectorsBOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced changes to its Board of Directors. John Ketchum has been appointed to join the Company’s Board of Directors. In addition, current director Aaron Davis has stepped down from his position. Both changes are effective immediately. “The addition of John Ketchum to our Board o |
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial OfficerJeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company, today an |
Tango Therapeutics Announces $80 million Private Placement FinancingBOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, has agreed to sell approximately 15.5 million shares of its common stock (“Common Stock”) (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private investment in public equity (PIPE) fi |